Scrip is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Pfizer/Lilly's Tanezumab Reduces Osteoarthritis Pain, But Is It Safe?

Executive Summary

Pfizer and Lilly said tanezumab reduced pain in a Phase III osteoarthritis study, but safety is the biggest question for NGF inhibitors. Yet, while Regeneron and Teva discontinued dosing for their fasinumab at its highest dose, tanezumab was effective at both doses in its first Phase III test.


Related Content

Lilly Has A Couple Of Controversies To Cover During Earnings Call
Lilly/Pfizer’s Tanezumab Safety Takes A Hit With Latest Phase III Results
Tanezumab Dances Through Back Pain Studies With “Acceptable” Safety Answers
Regeneron Tries To Put Focus On PD-1 Program, Not Sluggish Autoimmune Sales
Pfizer Exits Early Neuroscience, But M&A Could Allow Later Re-Entry
Regeneron’s Fasinumab Brings Second Clinical Hold For Anti-NGF Class
Lilly Shows Off R&D Progress With A Pain Franchise Built On New Mechanisms
Pfizer/Lilly ready to ditch painful past with new tanezumab trials
Regeneron, J&J, AstraZeneca Pull Plug On NGF Inhibitors In Development For Pain Indications
Pfizer forced to discontinue more trials for novel pain drug tanezumab


Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts